Ensign Peak Advisors’s BioCryst Pharmaceuticals BCRX Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Shares Change % | Capital Flow | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2025
Q2 | $792K | Hold |
88,400
| – | – | ﹤0.01% | 1383 |
|
|
2025
Q1 | $663K | Hold |
88,400
| – | – | ﹤0.01% | 1456 |
|
|
2024
Q4 | $665K | Hold |
88,400
| – | – | ﹤0.01% | 1518 |
|
|
2024
Q3 | $672K | Hold |
88,400
| – | – | ﹤0.01% | 1521 |
|
|
2024
Q2 | $546K | Hold |
88,400
| – | – | ﹤0.01% | 1581 |
|
|
2024
Q1 | $449K | Sell |
88,400
-4,460
| -5% | -$22.7K | ﹤0.01% | 1646 |
|
|
2023
Q4 | $556K | Hold |
92,860
| – | – | ﹤0.01% | 1638 |
|
|
2023
Q3 | $657K | Hold |
92,860
| – | – | ﹤0.01% | 1479 |
|
|
2023
Q2 | $654K | Hold |
92,860
| – | – | ﹤0.01% | 1535 |
|
|
2023
Q1 | $774K | Buy |
92,860
+11,300
| +14% | +$94.2K | ﹤0.01% | 1441 |
|
|
2022
Q4 | $936K | Buy |
81,560
+28,200
| +53% | +$324K | ﹤0.01% | 1216 |
|
|
2022
Q3 | $672K | Buy |
53,360
+1,530
| +3% | +$19.3K | ﹤0.01% | 1302 |
|
|
2022
Q2 | $548K | Hold |
51,830
| – | – | ﹤0.01% | 1425 |
|
|
2022
Q1 | $843K | Hold |
51,830
| – | – | ﹤0.01% | 1300 |
|
|
2021
Q4 | $718K | Buy |
+51,830
| New | +$718K | ﹤0.01% | 1449 |
|